Brief: Eliem Therapeutics Inc Reports Cash, Cash Equivalents And Short- And Long-Term Marketable Securities Was $134.7 Million As Of June 30, 2022

Climb Bio

15/08/2022 11:17

Aug 15 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS INC- INITIATED PHASE 1 PHARMACOKINETIC
TRIAL
FOR ETX-155 WITH EXPECTED RESULTS IN Q4 2022
    * ELIEM THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND SHORT-
AND
LONG-TERM MARKETABLE SECURITIES WAS $134.7 MILLION AS OF JUNE
30, 2022
    * ELIEM THERAPEUTICS INC- CAPITAL NOW EXPECTED TO FUND
OPERATIONS
INTO 2025
    * ELIEM THERAPEUTICS INC- QTRLY NET LOSS $0.56 PER SHARE

Source text for Eikon:  ID:nGNX5TLv8B 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;;))